Privia Health Purchases Evolent's ACO Division to Enhance Value-Based Care
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Source: Benzinga
Acquisition Details: Privia Health Group, Inc. has agreed to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. for $100 million in cash, with an additional $13 million contingent on Medicare performance, expected to close in Q4 2025.
Impact on Operations: The acquisition will expand Privia's value-based care (VBC) attributed lives to approximately 1.5 million and enhance operational synergies for ACO-participating providers, while Evolent Health reaffirmed its financial guidance for Q3 and full-year 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EVH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EVH
Wall Street analysts forecast EVH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EVH is 9.33 USD with a low forecast of 5.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
13 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.230
Low
5.00
Averages
9.33
High
16.00
Current: 3.230
Low
5.00
Averages
9.33
High
16.00
About EVH
Evolent Health, Inc. is a health care company connecting care for people with complex conditions like cancer, cardiovascular disease, and musculoskeletal diagnoses. The Company offers primary solutions, including specialty care management services and administrative services. It provides comprehensive quality management for oncology and cardiology patients from diagnosis through advanced care planning services, as well as identifying quality, lowest cost of care for outpatient orthopedic surgeries. Its administrative services solution includes an integrated value-based care platform designed to help customers manage and administer patient health in a cost-effective manner.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Evolent Health Appoints New CFO Mario Ramos with $2.35M Stock Award
- Executive Appointment: Evolent Health has appointed Mario Ramos as the new Chief Financial Officer effective January 2, 2026, aiming to enhance the company's financial performance through his extensive financial management experience.
- Stock Award: The company granted Ramos a one-time inducement award of 587,500 restricted stock units valued at $2.35 million, reflecting the company's high expectations for his future contributions.
- Award Structure: The stock award will vest over three years, with 34% vesting on the first anniversary and 33% on each of the following two anniversaries, incentivizing Ramos to maintain a stable contribution to the company's long-term growth.
- Compliance: This stock award complies with New York Stock Exchange listing rules, ensuring transparency and compliance in the executive hiring process, which further enhances investor confidence.
Continue Reading
Evolent Health Grants CFO Mario Ramos $2.35M Inducement Award
- Executive Appointment: Evolent Health appointed Mario Ramos as Chief Financial Officer effective January 2, 2026, granting him 587,500 restricted stock units as an inducement award, which underscores the company's commitment to strengthening its executive team.
- Stock Award Value: The inducement award has a grant date value of $2.35 million, vesting over three years at 34%, 33%, and 33%, which not only incentivizes the new CFO's long-term commitment but also enhances the company's competitiveness in attracting top talent.
- Compliance Assurance: Evolent ensured that the stock award complies with New York Stock Exchange listing rules, reflecting the company's transparency and adherence to regulations in executive compensation, thereby boosting investor confidence.
- Strategic Development: By bringing in an experienced CFO, Evolent aims to optimize financial management and strategic planning to support its mission of improving health outcomes for people with complex conditions, driving future business growth.
Continue Reading